卵巢癌免疫治疗的预后预测指标

doi:10.12280/gjfckx.20220206

摘要/Abstract

摘要：

卵巢癌自身具有免疫原性并可被宿主免疫系统识别和攻击，免疫系统在卵巢癌的发病机制、疾病进展中起着非常重要的作用。近年来，多腺苷二磷酸核糖聚合酶抑制剂、抗血管生成药物和靶向同源重组缺陷等治疗药物已在卵巢癌维持治疗中得到广泛应用，这些药物极大地改善了患者的预后，显著提高了卵巢癌患者的生存期，延缓了复发。随着免疫治疗在临床中的不断应用，探索能够用于评估卵巢癌免疫治疗预后的相关预测指标极为重要，有效、便捷的预后指标能够为临床医师的诊疗及决策提供参考，目前评估卵巢癌预后的预测指标仍是面临的难题之一。综述免疫评分、程序性细胞死亡受体1、中性粒细胞与淋巴细胞比值、骨髓源性抑制细胞等指标在卵巢癌免疫治疗预后中的预测价值。

关键词: 卵巢肿瘤, 免疫疗法, 预后, 程序性细胞死亡受体1, 免疫评分

Abstract:

Ovarian cancer has its own immunogenicity and can be recognized and attacked by the host immune system, which plays a very important role in the pathogenesis and disease progress of ovarian cancer. In recent years, drugs such as poly- adenosine diphosphate polymerase inhibitors, anti-angiogenesis drugs and targeted homologous recombination defects have been widely used in the maintenance treatment of ovarian cancer. These drugs have greatly improved the prognosis of patients, significantly improved the survival time of ovarian cancer patients, and delayed the recurrence. With the continuous application of immunotherapy in clinic, it is extremely important to explore the relevant predictive indicators that can be used to evaluate the prognosis of ovarian cancer immunotherapy. Effective and convenient prognostic indicators can provide reference for clinicians′ diagnosis, treatment and decision-making. At present, it is still one of the difficulties to evaluate the prognostic indicators of ovarian cancer. This paper reviews the predictive value of immune score, programmed cell death receptor 1, neutrophil-to-lymphocyte ratio, bone marrow-derived suppressor cells and other indicators in the prognosis of ovarian cancer immunotherapy.

Key words: Ovarian neoplasms, Immunotherapy, Prognosis, Programmed cell death receptor 1, Immunoscore

屈星, 韩逢皎, 马丽, 王晓慧. 卵巢癌免疫治疗的预后预测指标[J]. 国际妇产科学杂志, 2022, 49(6): 626-629.

QU Xing, HAN Feng-jiao, MA Li, WANG Xiao-hui. Prognostic Indicators of Ovarian Cancer in Immunotherapy[J]. Journal of International Obstetrics and Gynecology, 2022, 49(6): 626-629.

参考文献 33

[1]	Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review[J]. Semin Oncol Nurs, 2019, 35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. doi: S0749-2081(19)30012-9 pmid: 30867104
[2]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135(5):584-590. doi: 10.1097/CM9.0000000000002108. doi: 10.1097/CM9.0000000000002108
[3]	Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in Ovarian Cancer: Are We There Yet?[J]. J Clin Oncol, 2019, 37(27):2460-2471. doi: 10.1200/JCO.19.00508. doi: 10.1200/JCO.19.00508 pmid: 31403857
[4]	向莉, 王爱荣, 江高峰. 肿瘤免疫循环调节研究进展[J]. 肿瘤药学, 2021, 11(4):420-425. doi: 10.3969/j.issn.2095-1264.2021.04.06. doi: 10.3969/j.issn.2095-1264.2021.04.06
[5]	陈俊臣, 彭燕蓁, 成九梅. 卵巢癌免疫逃逸机制的研究进展[J]. 重庆医学, 2022, 51(10):1769-1773. doi:10.3969/j.issn.1671-8348.2022.10.032. doi: 10.3969/j.issn.1671-8348.2022.10.032
[6]	Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy[J]. J Cell Physiol, 2019, 234(10):16824-16837. doi: 10.1002/jcp.28358. doi: 10.1002/jcp.28358 pmid: 30784085
[7]	Zhang X, Yang J, Du L, et al. The prognostic value of Immunoscore in patients with cancer: A pooled analysis of 10,328 patients[J]. Int J Biol Markers, 2020, 35(3):3-13. doi: 10.1177/1724600820927409. doi: 10.1177/1724600820927409
[8]	Marliot F, Chen X, Kirilovsky A, et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer[J]. J Immunother Cancer, 2020, 8(1):e000272. doi: 10.1136/jitc-2019-000272. doi: 10.1136/jitc-2019-000272
[9]	Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer[J]. Curr Opin Immunol, 2013, 25(2):261-267. doi: 10.1016/j.coi.2013.03.004. doi: 10.1016/j.coi.2013.03.004 pmid: 23579076
[10]	Marliot F, Lafontaine L, Galon J. Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives[J]. Methods Enzymol, 2020, 636:109-128. doi: 10.1016/bs.mie.2019.07.018. doi: 10.1016/bs.mie.2019.07.018
[11]	Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction[J]. J Clin Oncol, 2011, 29(6):610-618. doi: 10.1200/JCO.2010.30.5425. doi: 10.1200/JCO.2010.30.5425 pmid: 21245428
[12]	Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective[J]. Cancer Res, 2007, 67(5):1883-1886. doi: 10.1158/0008-5472.CAN-06-4806. doi: 10.1158/0008-5472.CAN-06-4806 pmid: 17332313
[13]	Bösmüller HC, Wagner P, Peper JK, et al. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer[J]. Int J Gynecol Cancer, 2016, 26(4):671-679. doi: 10.1097/IGC.0000000000000672. doi: 10.1097/IGC.0000000000000672
[14]	Cong S, Guo Q, Cheng Y, et al. Immune Characterization of Ovarian Cancer Reveals New Cell Subtypes With Different Prognoses, Immune Risks, and Molecular Mechanisms[J]. Front Cell Dev Biol, 2020, 8:614139. doi: 10.3389/fcell.2020.614139. doi: 10.3389/fcell.2020.614139
[15]	Liu C, Seeram NP, Ma H. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review[J]. Cancer Cell Int, 2021, 21(1):239. doi: 10.1186/s12935-021-01946-4. doi: 10.1186/s12935-021-01946-4 pmid: 33906641
[16]	Wieser V, Gaugg I, Fleischer M, et al. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer[J]. Oncotarget, 2018, 9(25):17501-17511. doi: 10.18632/oncotarget.24770. doi: 10.18632/oncotarget.24770
[17]	鞠策, 高景春, 张朋新, 等. PD-1和PD-L1在卵巢上皮性癌组织中的表达及其意义[J]. 中华妇产科杂志, 2020, 55(8):529-534. doi: 10.3760/cma.j.cn112141-20200301-00155. doi: 10.3760/cma.j.cn112141-20200301-00155
[18]	Buderath P, Mairinger F, Mairinger E, et al. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma[J]. Int J Gynecol Cancer, 2019, 29(9):1389-1395. doi: 10.1136/ijgc-2019-000609. doi: 10.1136/ijgc-2019-000609 pmid: 31492714
[19]	Yin X, Wu L, Yang H, et al. Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis[J]. Medicine(Baltimore), 2019, 98(45):e17475. doi: 10.1097/MD.0000000000017475. doi: 10.1097/MD.0000000000017475
[20]	陈智丹, 张远起. 中性粒细胞与淋巴细胞比值对恶性肿瘤预后的影响[J]. 医学信息, 2021, 34(8):57-59. doi: 10.3969/j.issn.1006-1959.2021.08.015. doi: 10.3969/j.issn.1006-1959.2021.08.015
[21]	Viñal D, Gutierrez-Sainz L, Martinez D, et al. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy[J]. Clin Transl Oncol, 2021, 23(6):1185-1192. doi: 10.1007/s12094-020-02509-1. doi: 10.1007/s12094-020-02509-1 pmid: 33226553
[22]	Zhou Q, Hong L, Zuo MZ, et al. Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients[J]. Oncotarget, 2017, 8(40):68938-68949. doi: 10.18632/oncotarget.20196. doi: 10.18632/oncotarget.20196 pmid: 28978169
[23]	平文萍, 张羡, 王晓玉. 中性粒细胞与淋巴细胞比率对卵巢癌的预后价值及临床病理参数影响相关meta分析[J]. 现代医药卫生, 2021, 37(18):3111-3117. doi: 10.3969/j.issn.1009-5519.2021.18.014. doi: 10.3969/j.issn.1009-5519.2021.18.014
[24]	Ameratunga M, Chénard-Poirier M, Moreno Candilejo I, et al. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors[J]. Eur J Cancer, 2018, 89:56-63. doi: 10.1016/j.ejca.2017.11.012. doi: S0959-8049(17)31409-0 pmid: 29227818
[25]	Li T, Liu T, Zhu W, et al. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects[J]. Clin Med Insights Oncol, 2021, 15: 11795549211035540. doi: 10.1177/11795549211035540. doi: 10.1177/11795549211035540
[26]	Yaseen MM, Abuharfeil NM, Darmani H, et al. Recent advances in myeloid-derived suppressor cell biology[J]. Front Med, 2021, 15(2):232-251. doi: 10.1007/s11684-020-0797-2. doi: 10.1007/s11684-020-0797-2
[27]	闵珂婷, 张一国, 杨浩, 等. 间充质干细胞对髓源性抑制细胞免疫应答负性调控作用的影响[J]. 中国组织工程研究, 2022, 26(19):3084-3089. doi: 10.12307/2022.390. doi: 10.12307/2022.390
[28]	Sanchez-Pino MD, Dean MJ, Ochoa AC. Myeloid-derived suppressor cells (MDSC): When good intentions go awry[J]. Cell Immunol, 2021, 362:104302. doi: 10.1016/j.cellimm.2021.104302. doi: 10.1016/j.cellimm.2021.104302
[29]	Komura N, Mabuchi S, Shimura K, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer[J]. Cancer Immunol Immunother, 2020, 69(12):2477-2499. doi: 10.1007/s00262-020-02628-2 doi: 10.1007/s00262-020-02628-2
[30]	Li X, Wang J, Wu W, et al. Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway[J]. Febs J, 2020, 287(23):5218-5235.
[31]	Okła K, Czerwonka A, Wawruszak A, et al. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer[J]. Front Immunol, 2019, 10:691. doi: 10.3389/fimmu.2019.00691 pmid: 31001284
[32]	Duraiswamy J, Freeman G J, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer[J]. Cancer Res, 2013, 73(23):6900-6912. doi: 10.1158/0008-5472.CAN-13-1550 pmid: 23975756
[33]	Koh J, Kim Y, Lee K Y, et al. MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC[J]. Eur J Immunol, 2020, 50(11):1810-1819.